An observational study in Chronic Graft vs. Host Disease, sponsored by National Cancer Institute (NCI). Recruiting at 1 site in United States. Open to participants aged 1 Year to 120 Years. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by National Cancer Institute (NCI) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Graft vs Host Disease by National Cancer Institute (NCI) — 2 open to participants now, 4 under way, none of them phase 3. Graft vs Host Disease · National Cancer Institute (NCI).
Among the 15 studies in Graft vs Host Disease by National Cancer Institute (NCI), this one is one of 2 that started in 2004, is one of 4 observational ones, and was the 4th registered.
804 studies on the registry are indexed under Graft vs Host Disease; 147 are open to participants now.
Browse Graft vs Host Disease studies →2 of the 15 studies in Graft vs Host Disease by National Cancer Institute (NCI) are open now, in 1 country. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
By country, each count listing its studies:
Of the 101 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 40 (40%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.
This study: 1 Year to 120 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 1
First in 1996; this study’s year is marked. 2 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 650 is above the median of 72 across 98 observational studies indexed under Graft vs Host Disease.
Median enrollment 30 across the 11 interventional studies, 84 across the 4 observational. Of the 11 that completed or were terminated, 6 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
National Cancer Institute (NCI) is the lead sponsor of 3,557 studies on the registry; 335 are open to participants now.
Of its 412 completed or terminated interventional studies of FDA-regulated products, 374 (91%) have results posted.
2 of the studies in Graft vs Host Disease by National Cancer Institute (NCI) that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04044365National Cancer Institute (NCI)Pediatric cGVHD Symptom Scale | 2026-12-31 |
| NCT05531786National Cancer Institute (NCI)Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) | 2027-07-22 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies in Graft vs Host Disease by National Cancer Institute (NCI), from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Background:
Objectives:
Eligibility:
-Patients age 1 and older referred by the primary transplant physician for the evaluation of chronic graft-versus-host disease independent of underlying diagnosis.
Design:
Background:
Objectives:
Eligibility:
-Patients age 1 and older referred by the primary transplant physician for the evaluation of chronic graft-versus-host disease independent of underlying diagnosis.
Design:
Patients will be selected via referrals or from patients who were on companion clinical protocols at the NIH.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Any patient age 1 and older referred by the primary transplant physician for the evaluation of chronic independently of age or underlying diagnosis
EXCLUSION CRITERIA:
Patients who in the PIs assessment have a \<3 months.
Note: Because it is not always possible to make a clear clinical distinction between acute and chronic , patients with acute GVHD are not a-priori excluded until the possibility of chronic GVHD is reliably excluded on the basis of the clinical assessments in the cGVHD clinic.
Inclusion Criteria for control subjects without cGVHD:
Exclusion Criteria for control subjects without cGVHD:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who have undergone an allogeneic stem cell transplant and are diagnosed with cGVHD
Pediatric patients who have undergone an allogeneic stem cell transplant and are diagnosed with cGVHD
Patients who have undergone an allogeneic stem cell transplant and choose to submit biopsy, blood and urine samples only
Patients who have undergone an allogeneic stem cell transplant and are not diagnosed with cGVHD
To prospectively identify candidate markers for clinical and biological prognostic factors in patients with cGVHD and develop a prognostic model
Patient evaluations resulting in collection of data via several medical specialties; data will be examined individually and against clinical outcomes.
Time frame: 2 years + 3 months after protocol entry
To improve our current understanding of the biology of cGVHD-associated graft-versus-tumor effects (GVT).
Studying mechanisms of how cGVHD exerts its anti-cancer effects via laboratory analysis.
Time frame: ongoing
To identify potential clinical and biological markers of cGVHD activity
Assessment of risk and outcome as related to molecular markers of pathogenesis and/or stage of disease.
Time frame: ongoing
To identify novel biological characteristics of cGVHD and to describe them in the context of clinical history and presentation
Through collection of data via several medical specialties, assess the weight of specific clinical and biological characteristics and disease severity scales for predicting major clinical outcomes.
Time frame: ongoing
To establish a multidisciplinary clinic infrastructure for study of pathogenesis and natural history of cGVHD
Assessment of clinical and biological characteristics of cGVHD.
Time frame: ongoing
To develop clinically relevant cGVHD grading scales
Develop appropriate staging as a tool for measuring responses or outcomes in clinical studies through prospective collection and analysis of data.
Time frame: ongoing
Plan to share: Yes — All IPD recorded in the medical record will be shared with intramural investigators upon request. @@@@@@@@@@@@In addition, all large scale genomic sequencing data will be shared with subscribers to dbGaP.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Clinical data available during the study and indefinitely.@@@@@@@@@@@@Genomic data are available once genomic data are uploaded per protocol GDS plan for as long as database is active.
Access criteria: Data from this study may be requested by contacting the PI.@@@@@@@@@@@@Genomic data are made available via dbGaP through requests to the data custodians.
Started Oct 2004 (actual).
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Cancer Institute (NCI) →